Rolling Biologics License Application submitted to FDA for balstilimab for treatment of recurrent or metastatic cervical cancer

Data to support this filing come from phase II study in more than 160 patients treated with this anti-PD-1 human monoclonal antibody as monotherapy in second line setting, indicating response rates of 14% in overall study population and 19% in PD-L1 positive patients.

Source:

Biospace Inc.